Abstract 449P
Background
Improved cancer survival rates have escalated the demand for sustainable supportive care for survivors. Nasopharyngeal cancer (NPC) survivors often grapple with lasting radiation side effects. The M. D. Anderson Symptom Inventory - Head & Neck Module - Chinese version (MDASI-HN-C) has previously been validated for NPC patients undergoing radiation therapy (RT), but not for survivors. This study aims to psychometrically validate the MDASI-HN-C for NPC survivors.
Methods
In this single-centre cross-sectional study, 200 NPC survivors who completed RT with or without chemotherapy between three and 120 months were surveyed. The internal consistency reliability, convergent, and construct validity of the MDASI-HN-C were evaluated using Cronbach’s alpha (α) test, Pearson’s correlation (r), and exploratory factor analysis (EFA), respectively.
Results
All three subscales of the MDASI-HN-C exhibited strong internal consistency, with α ranging from 0.855 to 0.911. The MDASI-HN-C subscales were negatively correlated with the total score (r = -0.538 to -0.612; all p < 0.001), physical (r = -0.679 to -0.787; all p < 0.001), emotional (r = -0.536 to -0.625; all p < 0.001), functional (r = -0.307 to -0.390; all p < 0.001), and HN-specific (r = -0.587 to -0.616; all p < 0.001) domains of the Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN) scale. No correlations were identified between any subscales and the social/family domain. The MDASI-HN-C subscales were also positively correlated with the total score of the Cancer Survivors’ Unmet Needs Measure (CaSUN) (r = 0.414 to 0.468; all p < 0.001). Two factors for the 13 core items were identified by EFA, while only one factor each was found for the HN-specific and interference items. Noteworthily, open-ended responses indicated significant concerns about hearing loss and tinnitus among NPC survivors.
Conclusions
The MDASI-HN-C is a robust tool with satisfactory psychometric properties for assessing symptom burden among NPC survivors. The inclusion of 'hearing problems' as an additional item would enhance its applicability by capturing sensorial disturbances that significantly affect this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract